DESTINY-BTC01 — Phase 3 Clinical Trial
A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First-Line Locally Advanced or Metastatic HER2-Expressing Biliary Tract Cancer.
